Scene investigation represents the first step in the forensic evaluation of SCD and provides essential contextual information for guiding subsequent diagnostic procedures. The investigation helps reconstruct the circumstances of death and distinguish natural cardiac events from trauma, intoxication, or environmental causes^[30].

In SCD cases, the evidentiary value of scene examination lies less in descriptive documentation and more in identifying factors that may suggest arrhythmogenic triggers or underlying disease. Particular attention should be paid to circumstances of death, including physical exertion, emotional stress, or occurrence during sleep, as these patterns are often associated with specific pathological substrates. For example, exertional collapse may indicate cardiomyopathies, whereas nocturnal deaths raise suspicion for channelopathies such as Brugada syndrome (BrS)^[31].

The collection of medical and family history is equally critical, especially in cases involving young individuals. Information on prior syncope, seizures, cardiac symptoms, or familial sudden death may point toward inherited arrhythmogenic disorders, which frequently remain clinically silent until the fatal event^[32].

In addition, documentation of potential exogenous triggers, including pharmaceuticals, illicit substances, energy drinks, or supplements, is essential, as stimulant exposure may precipitate fatal arrhythmias in susceptible individuals^[33]. When present, implantable cardiac devices should be interrogated, as stored data can provide direct evidence of terminal arrhythmic events^[34].

Although scene findings are rarely diagnostic when considered individually, their integration with autopsy and laboratory results contributes to a structured evidentiary framework, improving both the accuracy of cause-of-death determination and the identification of clinically relevant risk factors^[35,36].

A standardized autopsy remains the cornerstone of SCD investigation and is essential for identifying structural and non-structural causes of death. Current guidelines emphasize a systematic approach that prioritizes detailed examination of the cardiovascular system while maintaining a comprehensive evaluation of extracardiac findings^[1].

External examination primarily serves to document signs of medical intervention, trauma related to collapse or features suggestive of intoxication or systemic disease. Although typically non-specific, these findings may provide important contextual clues that support or refute a cardiac cause of death^[37].

The internal examination is centered on meticulous assessment of the heart, coronary arteries, and great vessels. Serial sectioning of the coronary arteries at short intervals is essential for detecting atherosclerotic stenosis, plaque disruption, and thrombosis, which represent the predominant substrates of SCD in adult populations^[38-41].

However, a key limitation of conventional autopsy is the inability to identify abnormalities in a subset of cases. Approximately 10%-15% of SCD cases remain unexplained following macroscopic and histological evaluation, reflecting underlying electrical disorders or subtle pathological changes not detectable by morphology alone^[10]. In these situations, additional investigations, particularly genetic and toxicological analyses, become essential for clarifying the cause of death.

Sampling strategies must therefore be systematic and sufficiently extensive, including multiple myocardial regions and, when appropriate, conduction system evaluation. Special attention is required in young individuals, in whom pathological alterations may be focal or minimal^[42].

Beyond cause-of-death determination, the autopsy provides critical data for epidemiological surveillance and may reveal previously undiagnosed conditions with implications for family screening. This broader role underscores the importance of standardized protocols and multidisciplinary interpretation in modern SCD investigation^[24,43].

Detailed cardiac examination represents the most critical component of the SCD autopsy, as it allows differentiation between ischemic, structural, inflammatory, and congenital causes of death^[1,9].

At the macroscopic level, assessment includes heart weight, chamber dimensions, wall thickness, and global morphology. These parameters provide essential clues to underlying disease processes, such as hypertrophic remodeling, dilated cardiomyopathy, or right ventricular abnormalities suggestive of arrhythmogenic cardiomyopathy (ACM). Systematic examination of coronary arteries remains fundamental for identifying atherosclerosis, plaque rupture, and thrombosis, which predominate in older individuals^[44]. Beyond the identification of obstructive lesions, detailed assessment of coronary artery pathology allows characterization of plaque composition, distribution, and stage of evolution. These features are central to vascular medicine, as they reflect the dynamic process of atherosclerosis progression and instability^[45]. Forensic evaluation thus provides a unique opportunity to directly observe advanced and subclinical vascular disease, including diffuse atherosclerosis and early plaque formation, which may remain undetected during life.

Importantly, gross findings may be subtle or absent in several conditions associated with SCD, including myocarditis and conduction system abnormalities, highlighting the limitations of macroscopic evaluation alone^[46].

Histological analysis is therefore indispensable and requires standardized sampling from multiple myocardial regions. Routine staining allows identification of key pathological features, including myocardial necrosis, inflammation, fibrosis, myocyte disarray, and fibrofatty replacement. These findings are central to diagnosing conditions such as hypertrophic cardiomyopathy (HCM), ACM, and myocarditis^[47].

Nevertheless, early myocardial injury, particularly in the context of acute ischemia, remains challenging to detect using conventional histology alone, representing a significant diagnostic limitation. Similarly, inflammatory processes may be focal and easily missed without adequate sampling. These challenges emphasize the need for comprehensive and standardized histological protocols as a prerequisite for accurate diagnosis.

The integration of macroscopic and microscopic findings thus provides the structural framework for interpreting SCD, which must subsequently be complemented by ancillary investigations and clinical context.

Ancillary investigations are essential for resolving diagnostically inconclusive cases and for identifying non-structural mechanisms of sudden death. These investigations include toxicological, microbiological, molecular, genetic, imaging, and immunohistochemical analyses. Rather than acting as isolated tests, these methods serve as complementary diagnostic tools that extend the diagnostic capabilities of conventional autopsy^[24].

Toxicological analysis is fundamental for detecting substances capable of inducing arrhythmias, impairing conduction, or triggering ischemia. Comprehensive screening is often required, as polypharmacy and combined drug effects are common, and interpretation must account for postmortem redistribution and pharmacokinetic variability^[48].

Microbiological and molecular investigations are indicated when infectious or inflammatory etiologies, such as myocarditis, are suspected. Targeted detection of cardiotropic viruses can provide critical evidence in otherwise inconclusive cases^[49].

In parallel, molecular autopsy has emerged as a key diagnostic tool, particularly in autopsy-negative SCD, with direct implications for family screening and prevention^[50].

Despite their increasing relevance, ancillary investigations are characterized by important limitations, including interpretative uncertainty, lack of standardization, and variability in availability across forensic settings. Their diagnostic value is therefore maximized only when integrated with morphological findings, circumstantial data, and clinical information within a multidisciplinary framework.

The overall forensic workflow in SCD, from scene investigation to molecular analysis, forms a structured and hierarchical process in which each step contributes to refining the final diagnosis and, importantly, to translating postmortem findings into preventive strategies [Figure 1].

CAD remains the leading cause of SCD in individuals over 35 years, accounting for approximately 70%-75% of cases^[51]. In this context, SCD most commonly results from acute ischemia due to plaque disruption or thrombosis, which rapidly destabilizes myocardial electrical activity^[3]. Advanced atherosclerosis, multivessel involvement, and calcified lesions further increase the arrhythmogenic substrate^[52].

From a vascular medicine perspective, these findings should be interpreted within the broader framework of systemic atherosclerotic disease. The presence of complex coronary plaques at autopsy often reflects a long-standing, clinically silent process of vascular injury and remodeling^[53]. Importantly, features such as thin cap fibroatheroma, plaque erosion, and diffuse non-obstructive atherosclerosis are increasingly recognized as markers of vulnerability rather than simply luminal stenosis^[54]. In this context, forensic identification of plaque morphology provides unique insights into mechanisms of plaque instability and may contribute to refining vascular risk stratification models beyond traditional clinical parameters.

An additional vascular substrate that deserves consideration is coronary microvascular dysfunction (CMD), which encompasses structural and functional abnormalities of the coronary microcirculation capable of impairing myocardial perfusion independently of significant epicardial coronary stenosis. Increasing evidence indicates that CMD may promote myocardial ischemia, electrical instability, and malignant ventricular arrhythmias, thereby contributing to SCD risk even in patients with non-obstructive coronary arteries^[55]. From a forensic perspective, CMD represents a particularly challenging entity because alterations such as arteriolar remodeling, endothelial dysfunction, capillary rarefaction, and impaired coronary flow reserve are often not appreciable during routine autopsy or conventional histopathological examinations. Consequently, a subset of ischemic or arrhythmic deaths may involve clinically significant microvascular disease that remains morphologically subtle, highlighting both the limitations of traditional postmortem assessment and the need for integrating vascular pathophysiology into the interpretation of autopsy-negative SCD cases^[56,57].

Plaque rupture involves disruption of a thin fibrous cap overlying a lipid-rich necrotic core, leading to thrombus formation and abrupt vessel occlusion^[53,54]. In contrast, plaque erosion is characterized by endothelial denudation without cap rupture and is typically associated with less lipid content and greater extracellular matrix components^[55,56]. Both mechanisms can precipitate lethal ventricular arrhythmias within minutes of ischemia onset.

Myocardial infarction may lead to SCD either in the acute phase, through ischemia-induced arrhythmias, or in the chronic phase via scar-related re-entry circuits. A major challenge in forensic pathology is the detection of early myocardial ischemia, as histological signs may be minimal or absent within the first hours after onset^[58,59].

This limitation underscores a critical gap in morphology-based diagnosis and highlights the need for integrated approaches combining histology with ancillary investigations. From an epidemiological perspective, ischemic SCD frequently occurs in individuals with previously undiagnosed coronary disease, emphasizing the silent progression of atherosclerosis and the limitations of current clinical risk detection strategies^[60,61].

Cardiomyopathies represent the most important non-ischemic causes of SCD, particularly in younger individuals and athletes. Their pathological heterogeneity reflects diverse genetic and structural abnormalities that create substrates for malignant ventricular arrhythmias^[62,63].

HCM is a leading cause of SCD in adolescents and young adults and is classically characterized by asymmetric ventricular hypertrophy and myocyte disarray, although other morphological patterns, including concentric and apical hypertrophy, may also occur. These structural abnormalities, combined with interstitial fibrosis and small vessel disease, create an arrhythmogenic substrate particularly prone to instability during exertion or adrenergic stimulation^[4,64,65]. CMD plays a central role in the pathophysiology of HCM, contributing to ischemia, replacement fibrosis, and electrical instability even in the absence of epicardial coronary stenosis^[66]. This highlights how microvascular disease, often undetectable in standard clinical assessments, may represent a critical but underrecognized determinant of both SCD risk and broader cardiovascular morbidity.

ACM is defined by progressive fibrofatty replacement of the myocardium, predominantly involving the right ventricle but often extending to biventricular or left-dominant forms. These structural alterations disrupt electrical conduction and predispose individuals to ventricular arrhythmias, particularly during physical stress^[4,67]. Identification at autopsy has important implications for genetic testing and familial screening.

Dilated cardiomyopathy is characterized by ventricular dilation, systolic dysfunction, and diffuse myocardial fibrosis, all of which contribute to electrical instability. Although clinically associated with heart failure, SCD may occur even in early or mild symptomatic disease, reflecting the arrhythmogenic role of myocardial remodeling^[4,68,69].

Restrictive and infiltrative cardiomyopathies, including amyloidosis and metabolic storage disorders, are less frequent but clinically relevant causes of SCD. These conditions alter myocardial compliance and conduction, promoting arrhythmias or electromechanical dissociation. Their recognition is essential, as they often carry specific therapeutic and familial implications^[70-72].

Primary electrical disorders, or channelopathies, are characterized by lethal arrhythmias occurring in structurally normal hearts. Because they typically lack macroscopic or histological abnormalities, they represent a central component of autopsy-negative SCD^[20].

Channelopathies, including long QT syndrome (LQTS), BrS, and catecholaminergic polymorphic ventricular tachycardia (CPVT), are major causes of SCD in individuals under 35 years^[51]. Their clinical presentation is often unpredictable, with sudden death occurring during exertion, emotional stress, or sleep.

LQTS is characterized by delayed repolarization and susceptibility to polymorphic ventricular tachycardia, typically associated with ion channel gene mutations^[73,74].

BrS involves sodium channel dysfunction and is associated with nocturnal arrhythmic events, particularly in young men^[75].

CPVT results from abnormalities in calcium handling and manifests with stress-induced arrhythmias without structural heart disease^[76].

A key limitation in forensic investigation is that conventional autopsy cannot identify these disorders. Consequently, molecular autopsy has become essential, although interpretation remains complex due to the high prevalence of variants of uncertain significance (VUS) and the need for integration with clinical and familial data^[50,77].

Myocarditis is a clinically and pathologically heterogeneous condition that can lead to SCD across all age groups. Its presentation ranges from subclinical inflammation to fulminant disease, often complicating diagnosis^[78].

Viral myocarditis is the most common form and is characterized histologically by lymphocytic infiltration and myocyte necrosis. It represents a well-recognized cause of SCD in children and young adults^[79,80]. Autoimmune forms, including giant cell myocarditis and cardiac sarcoidosis, are associated with aggressive inflammatory processes, conduction system involvement, and high arrhythmic risk^[81,82]. Toxic myocarditis, related to drug exposure or environmental toxins, further contributes to the spectrum of inflammatory cardiac disease^[83,84].

A major limitation in diagnosis is the patchy distribution of inflammatory infiltrates, which may lead to false-negative findings if sampling is insufficient. This highlights the importance of extensive histological evaluation and complementary molecular techniques^[78,85].

Cases in which the heart appears structurally normal at autopsy represent one of the most challenging categories in forensic pathology. Approximately 10%-15% of SCD cases fall into this group, often designated as sudden unexplained death or SADS^[86].

These autopsy-negative SCD cases are more common in younger individuals and are frequently linked to inherited arrhythmogenic disorders or subtle pathological changes not detectable by conventional methods^[20].

The absence of structural abnormalities underscores the limitations of morphology-based diagnosis and the need for advanced investigative approaches.

Although meticulous histological examination may reveal subtle alterations, many cases remain unresolved without genetic analysis. Molecular autopsy using NGS has therefore become an indispensable diagnostic tool, allowing identification of pathogenic variants and enabling targeted family screening^[87-89].

However, significant challenges remain, particularly in the interpretation of genetic findings. The high prevalence of VUS limits diagnostic certainty and requires cautious evaluation through population data, in silico analysis, and family-based studies^[90,91].

In Table 1, age-related distribution and pathological features of SCD are summarized.

Postmortem imaging has become an increasingly valuable adjunct to conventional autopsy, offering non-invasive assessment and whole-body documentation. Post-mortem computed tomography (PMCT) is particularly useful for detecting skeletal injuries, gas distribution, coronary calcifications, and medical devices, and facilitates targeted dissection^[92,99]. In cardiovascular SCD, the addition of postmortem CT angiography (PMCTA) improves visualization of coronary arteries, enabling detection of stenoses and occlusions that may not be readily apparent on standard imaging^[93]. Post-mortem magnetic resonance imaging (PMMRI), in contrast, provides superior soft-tissue characterization and may reveal myocardial edema or structural abnormalities suggestive of acute injury^[92,100].

Ex situ PMMRI has shown promising concordance with macroscopic and histological findings, assisting in the identification of subtle lesions and guiding sampling strategies^[101,102].

Despite these advantages, imaging techniques remain adjunctive rather than definitive. Their sensitivity for early ischemic changes and inflammatory processes is limited, and interpretation is often complicated by postmortem artifacts and tissue degradation. Consequently, imaging findings must be integrated with autopsy and histological data to ensure accurate cause-of-death determination^[93].

Molecular autopsy is now a key component of SCD investigation, particularly in cases where structural abnormalities are absent. It involves postmortem genetic testing aimed at identifying inherited arrhythmogenic conditions, including channelopathies and cardiomyopathies^[50].

NGS technologies have significantly expanded the scope of analysis, allowing simultaneous interrogation of multiple genes associated with cardiac function. Targeted gene panels are commonly used in forensic practice, while whole-exome (WES) and whole-genome sequencing (WGS) provide broader coverage at the cost of increased analytical complexity^[50,103].

The diagnostic yield of molecular autopsy is highest in younger individuals, with pathogenic variants identified in approximately 20%-25% of autopsy-negative SCD cases^[20]. Importantly, these findings have implications beyond postmortem diagnosis, enabling cascade screening and preventive management of at-risk relatives.

However, interpretation of genetic variants remains a major limitation. A substantial proportion of findings are classified as VUS, which complicates clinical translation and may lead to misinterpretation if not contextualized appropriately^[104]. Diagnostic accuracy is therefore maximized through multidisciplinary evaluation and, when possible, correlation with family history and clinical phenotype [Table 4].

From a practical perspective, VUS should not be considered diagnostic and should not independently guide predictive testing or clinical management in relatives. Current recommendations emphasize referral of affected families to specialized multidisciplinary cardiac genetic clinics, where variant interpretation can be integrated with phenotypic evaluation, segregation studies, and periodic reclassification efforts^[90,105]. To minimize unnecessary anxiety and inappropriate clinical interventions, some experts also advocate restricting the clinical emphasis of postmortem genetic reports to Pathogenic and Likely Pathogenic variants while clearly distinguishing VUS as findings requiring further investigation rather than actionable results^[29,91].

An additional challenge arises from variability in variant interpretation across laboratories and institutions. Although current recommendations encourage the use of standardized classification frameworks, including American College of Medical Genetics and Genomics/Association for Molecular Pathology criteria, differences in available population databases, bioinformatic pipelines, expert interpretation, and institutional reporting policies may result in divergent classifications for the same variant. Consequently, findings considered potentially relevant in one center may be interpreted differently elsewhere, highlighting the need for greater harmonization and centralized expert review.

Despite its diagnostic value, the implementation of molecular autopsy in routine practice is significantly constrained by practical and interpretative barriers. The cost of NGS, together with the need for specialized laboratory infrastructure and bioinformatic expertise, limits its availability to selected centers, resulting in unequal access across forensic systems. In addition, the high prevalence of VUS, which may account for approximately 50%-60% of detected genetic variants in molecular autopsy analyses, represents a major challenge for clinical translation, as it introduces uncertainty in causal attribution and risk assessment^[20,50]. Consequently, the diagnostic yield reported across studies varies considerably, reflecting differences in methodology, population characteristics, and criteria for variant classification.

In forensic practice, excessive reliance on genetic findings without adequate phenotypic correlation may lead to inappropriate attribution of causality. The identification of a rare genetic variant does not necessarily establish the cause of death, particularly when pathological evidence is absent or inconclusive. Therefore, molecular findings should be regarded as one component of a comprehensive multidisciplinary assessment rather than as standalone diagnostic evidence.

Ethical and legal considerations further complicate implementation, particularly with regard to consent for postmortem genetic testing, management of genetic data, and communication of results to relatives, who may be directly affected by the findings. In this context, the development of standardized variant interpretation frameworks, multidisciplinary case review, and structured genetic counseling is essential to ensure appropriate use and to avoid overinterpretation or misclassification of genetic results^[105-107].

Epigenetic and transcriptomic profiling represents a rapidly evolving field in forensic medicine, offering insight into dynamic molecular processes that are not captured by static structural or genetic analyses^[108,109]. Among these, microRNAs (miRNAs) have emerged as particularly promising biomarkers due to their postmortem stability and tissue-specific expression patterns. Experimental and computational studies suggest that miRNA signatures may reflect early ischemic injury and arrhythmogenic processes, with potential applications in distinguishing causes of SCD^[21,22].

Transcriptomic profiling may provide insight into inflammatory pathways and metabolic alterations associated with myocardial injury, although its application remains largely confined to research settings^[110].

Despite their potential, these approaches are not yet standardized for routine forensic use. Variability in sample quality, postmortem degradation, and lack of validated reference datasets currently limit their clinical applicability.

In addition, the lack of validated reference databases and the susceptibility of RNA-based analyses to postmortem degradation pose further challenges. Standardization of sampling procedures and development of robust analytical pipelines will be crucial to translate these approaches from research to routine application^[10]. Additional multicenter validation studies are required before transcriptomic and epigenetic analyses can be considered reliable diagnostic tools in SCD investigation.

Proteomic and metabolomic techniques may offer a functional perspective on myocardial injury by detecting molecular alterations that precede detectable structural changes. This is particularly relevant for early ischemia, where conventional histology may be inconclusive^[111].

Experimental studies suggest that metabolic shifts may occur within minutes of ischemia onset, affecting lipid metabolism and energy pathways before the appearance of morphological damage^[98]. Similarly, proteomic analyses have identified alterations in proteins involved in cytoskeletal organization, inflammation, and ion regulation, reflecting early pathophysiological responses^[112].

Although these findings highlight the diagnostic potential of proteomics and metabolomics, their routine application is currently limited by technical complexity, cost, and lack of standardized protocols. As such, they remain primarily research tools with promising future applications in forensic diagnostics.

At present, no proteomic or metabolomic marker panel has achieved sufficient validation to support routine forensic diagnosis of SCD. Most available studies are characterized by limited sample sizes, methodological heterogeneity, and lack of external validation cohorts. Consequently, while these approaches provide important mechanistic insights into myocardial injury and arrhythmogenesis, their current role should be considered exploratory rather than diagnostic. To address these barriers, future efforts should focus on identifying reproducible biomarker panels with clear diagnostic thresholds that can be implemented in a scalable manner across different resource settings^[97].

Biomarker-based approaches, including IHC and postmortem biochemistry, provide additional tools for evaluating cases in which structural findings are inconclusive. These methods are particularly relevant for distinguishing ischemic from arrhythmic mechanisms of death.

Immunohistochemical markers, such as complement components, cytoskeletal proteins, and membrane-associated molecules, can improve detection of early myocardial injury beyond the limits of routine histology^[18,94].

Similarly, redistribution patterns of ion-channel-related proteins may offer indirect evidence of arrhythmogenic mechanisms^[94,113].

Postmortem biochemical markers, including cardiac troponins, natriuretic peptides, and stress-related mediators, provide complementary information on myocardial damage and hemodynamic stress^[114-116].

A key limitation of biomarker-based approaches is the absence of specificity: no single marker reliably differentiates ischemic from arrhythmic death. Therefore, their diagnostic value lies primarily in their integration with histological, toxicological, and genetic findings rather than as standalone indicators^[117-119].

SCD in athletes demonstrates marked age-related variability, with cardiomyopathies and channelopathies predominating in younger individuals and CAD becoming more prevalent in older athletes^[120,121]. Although the absolute incidence is low, it varies significantly across sports, sex, and geographic regions, reflecting both biological and environmental factors^[122].

From a forensic perspective, the distribution of pathological substrates largely mirrors clinical observations. In individuals ≤ 35 years, HCM, ACM, myocarditis, and autopsy-negative SCD are most frequent, whereas atherosclerotic disease predominates beyond this age threshold^[120,121]. Notably, many sport-related deaths occur outside organized competition, highlighting that risk extends beyond elite athletes and supporting a broader population-based preventive approach^[123].

Forensic investigation must therefore include targeted cardiac examination, comprehensive toxicology, and molecular autopsy in cases without structural findings. While preparticipation screening may reduce risk, its effectiveness remains debated, and secondary prevention strategies, particularly access to automated external defibrillators (AEDs), represent a consistently supported intervention^{[120,121,124,125]}.

Importantly, forensic data contributes to refining risk communication and informing public health policies, particularly in high-risk sporting environments.

Sudden deaths in infants and children are characterized by diagnostic heterogeneity and persistent challenges in classification, particularly due to inconsistent terminology (e.g., SIDS, SUID, SUDC) and variability in investigative protocols^[126-128]. These limitations complicate both epidemiological surveillance and prevention strategies.

Standardized investigative frameworks integrating scene examination, structured autopsy, and systematic biological sampling have significantly improved case classification and research reliability^[105].

Among identified causes, myocarditis is increasingly recognized as an underdiagnosed contributor, with viral etiologies frequently confirmed through molecular techniques^[129]. In older children, inherited cardiomyopathies and channelopathies represent a substantial proportion of SCD, often presenting as autopsy-negative cases. Molecular autopsy has demonstrated a diagnostic yield of approximately 20%-28% in selected cohorts, reinforcing its role in pediatric forensic practice^[130].

From a forensic perspective, challenges include variability in scene investigation quality, limitations in histological sensitivity, and unequal access to genetic testing^[131].

The implications extend beyond diagnosis, as accurate classification supports both preventive public health interventions and identification of at-risk relatives.

Toxicological factors represent a major and often underappreciated component of SCD, particularly in cases with structurally normal hearts. In such contexts, comprehensive toxicological analysis is essential to identify potential pro-arrhythmic triggers and distinguish causation from incidental findings^[43]. Large cohort studies demonstrate a high prevalence of positive toxicology in medico-legal SCD cases, with polysubstance use frequently observed and associated with increased arrhythmic risk^[132,133]. Stimulants such as cocaine and amphetamines are particularly relevant due to their well-established effects on cardiac electrophysiology and coronary vasculature.

However, a key forensic challenge is the interpretation of toxicological findings. Postmortem redistribution, tolerance, and drug-drug interactions complicate attribution of causality, especially when structural abnormalities are minimal. Evidence suggests that toxicological factors may be causative in a subset of autopsy-negative cases, but overinterpretation remains a recognized risk^[133-135].

Accordingly, drug detection should neither be considered inherently causal nor dismissed as incidental; instead, interpretation must integrate pathological findings, circumstantial data, and pharmacological context.

Energy drinks and stimulant compounds have emerged as potential contributors to SCD, particularly in young individuals and those with underlying cardiac vulnerability. These products often contain high doses of caffeine and other sympathomimetic substances, which may modulate cardiac electrophysiology and increase arrhythmic risk^[136]. Clinical and forensic reports describe temporal associations between energy drink consumption and cardiac arrest, particularly in individuals with inherited arrhythmogenic conditions, although a direct causal relationship remains difficult to establish^[137]. Similarly, the use of prescription stimulants and novel psychoactive substances introduces additional complexity due to variable pharmacodynamics and limited toxicological characterization^[138].

The forensic challenge lies in distinguishing causal relationships from coincidental associations, particularly in the absence of structural heart disease. Accurate reconstruction of exposure history, combined with toxicological and pathological findings, is therefore essential. Reports should explicitly acknowledge uncertainty, especially when multiple potential triggers coexist^[139,140].

Sudden deaths occurring during medical procedures or supervised care require careful integration of clinical records, procedural context, and forensic findings. Potential mechanisms include drug-induced arrhythmias, electrolyte disturbances, hypoxia, or unrecognized underlying cardiac disease^[11,141,142].

In these cases, toxicology (including administered medications), review of monitoring data, and targeted histological analysis are essential to distinguish iatrogenic events from natural cardiac death. Molecular autopsy may be indicated when routine investigations are inconclusive^[24,143].

SCD in custodial environments presents complex medico-legal challenges, often involving potential interactions between underlying disease, stress, and substance use^[51].

Thorough investigation requires comprehensive scene analysis, full autopsy, broad toxicology, and, when necessary, ancillary molecular testing. Attention should be given to distinguishing natural cardiac death from non-cardiac causes such as asphyxia or trauma, especially in contested cases^[10,144].

Transparency in reporting and acknowledgment of diagnostic uncertainty are critical to ensure medico-legal credibility and public trust [Table 5].

Forensic investigation provides uniquely detailed, cause-specific data that complement clinical registries and enhance cardiovascular risk stratification at the population level^[145]. By incorporating postmortem findings into epidemiologic frameworks, forensic medicine contributes to a more accurate understanding of mortality patterns and supports evidence-based public health interventions. The translational impact of forensic findings is summarized in Table 6.

Autopsy-based studies consistently reveal the high prevalence of previously undiagnosed cardiovascular disease, including CAD, myocardial infarction, and hypertensive cardiac remodeling, even in individuals without prior clinical history^[146,147]. These findings highlight a substantial burden of silent or subclinical disease and expose limitations of current screening and prevention strategies. Importantly, these findings extend beyond diagnosis to the domain of vascular risk assessment. The detection of subclinical coronary atherosclerosis, plaque instability, and myocardial fibrosis at autopsy provides direct evidence of disease processes that are frequently underestimated or missed by conventional clinical screening tools^[148]. In this sense, forensic data contribute to redefining cardiovascular risk by incorporating morphological indicators of vascular vulnerability, complementing traditional risk factors such as hypertension, diabetes, and dyslipidemia.

Beyond disease detection, forensic data also identify systemic gaps in healthcare delivery and risk-factor management. Analyses of sudden deaths in community settings show that cardiovascular disease disproportionately affects specific demographic groups and that improved access to emergency response systems, including AEDs and bystander cardiopulmonary resuscitation, could significantly reduce mortality^[149,150].

In addition, forensic investigations provide insight into emerging public health threats, including substance misuse and environmental or behavioral risk factors, thereby informing targeted prevention policies^{[132-135,145,151]}. The integration of molecular and multi-omic data further extends this translational impact by enabling identification of novel disease mechanisms and potential therapeutic targets^[152-154].

Collectively, these observations position forensic medicine as a critical source of high-resolution epidemiologic intelligence, capable of informing both clinical risk stratification and population-level prevention strategies.

Importantly, risk stratification strategies should not be considered uniformly applicable across all populations. The pathological substrates underlying SCD differ substantially according to age, clinical setting, and genetic background. In older individuals, risk assessment is primarily focused on CAD and acquired cardiovascular risk factors, whereas younger populations are more frequently affected by inherited cardiomyopathies and channelopathies. Similarly, athletes, pediatric populations, and individuals with structurally normal hearts represent distinct groups requiring tailored approaches. Consequently, forensic findings should be integrated into population-specific risk models rather than applied through a universal risk-stratification framework.

Notwithstanding their translational potential, the incorporation of forensic findings into clinical and public health practice is influenced by disparities in healthcare infrastructure, access to genetic testing, and differences in medico-legal systems. These factors may limit the generalizability and implementation of preventive strategies derived from forensic data.

Postmortem investigation plays a central role in identifying inherited cardiovascular risk among relatives of SCD victims, particularly in cases where genetic conditions are involved. The identification of pathogenic or likely pathogenic variants through postmortem genetic investigation has important implications for surviving relatives, enabling cascade screening and individualized preventive strategies^{[108,155-158]}.

Once a pathogenic variant is identified, cascade screening enables early diagnosis and management of at-risk relatives through clinical surveillance, lifestyle modification, pharmacological therapy, and, in selected cases, implantable cardioverter-defibrillator implantation. This approach reflects the well-established genetic basis of many arrhythmogenic disorders and aligns with precision medicine strategies in cardiovascular care^[159].

However, challenges remain, particularly in the interpretation of genetic variants, including VUS. Recent advances in genomic analysis, including investigation of non-coding regulatory regions, highlight the complexity of inherited risk and the need for integrated interpretation combining genetic, clinical, and familial data^[160,161].

Overall, postmortem genetic investigation represents a critical entry point for familial prevention, enabling early identification of at-risk individuals and reducing the likelihood of recurrent SCD events within affected families.

The integration of forensic data into epidemiological registries is essential for improving the accuracy of cardiovascular mortality surveillance and refining risk stratification models. Unlike clinical registries, which may rely on incomplete or misclassified data, forensic investigations provide comprehensive and validated cause-of-death information derived from autopsy, toxicology, and molecular analysis^[145,162].

Established frameworks, such as the CDC Sudden Unexpected Infant Death and Sudden Death in the Young registries, demonstrate the value of systematically incorporating medico-legal data into public health infrastructures. These systems improve consistency of classification, enable large-scale epidemiological analyses, and support targeted preventive strategies^[163].

In the context of cardiovascular disease, integration of forensic findings into registries enhances recognition of undiagnosed conditions and reveals discrepancies between clinical diagnoses and true disease prevalence^[147]. Moreover, the inclusion of contextual factors, such as environmental conditions, substance exposure, and behavioral triggers, provides a more comprehensive understanding of risk patterns and supports development of tailored interventions^[151].

The incorporation of molecular autopsy further expands the potential of these registries by enabling genetic epidemiology studies, identification of familial clusters, and organization of cascade-screening programs^[157,158].

Ultimately, integrated forensic-epidemiological systems represent a key component of modern cardiovascular surveillance, enabling more precise estimation of disease burden and more effective public health responses.

Postmortem investigation of SCD increasingly serves as a bridge between diagnostic pathology and preventive cardiology. By identifying structural, genetic, and environmental determinants of fatal events, forensic findings can be translated into targeted strategies aimed at both individuals and populations.

At the individual level, postmortem genetic findings may support personalized prevention strategies in relatives identified through cascade screening. Beyond the diagnostic aspects discussed earlier, their principal value lies in guiding targeted clinical surveillance and risk reduction^[20,164,165].

At the mechanistic level, advances in postmortem analysis, including digital pathology and biomarker profiling, are revealing subtle structural and functional alterations associated with arrhythmic susceptibility. Emerging studies suggest that quantitative histological and computational approaches may identify previously unrecognized substrates, refining risk assessment in affected families^[166,167].

At the population level, forensic findings inform preventive strategies through improved risk stratification models and public health initiatives. Multidisciplinary frameworks integrating autopsy data, genetic information, and clinical risk factors are increasingly advocated to enhance early detection and prevention of SCD^[125,168]. The effectiveness of these strategies is likely to depend on the specific population under consideration. For example, genetic findings may have the greatest preventive impact in young individuals and families affected by inherited arrhythmogenic disorders, whereas autopsy evidence of coronary atherosclerosis and myocardial remodeling may provide greater value for risk assessment in older populations. These differences highlight the need for personalized and population-adapted prevention strategies.

These approaches also support investment in community-level interventions, including AED deployment and public education programs. In particular, the integration of forensic findings into vascular medicine frameworks may enhance current approaches to primary prevention. Autopsy evidence of non-obstructive coronary disease, microvascular dysfunction, and early myocardial remodeling supports the concept that structural vascular pathology often precedes clinical manifestation. Incorporating these insights into risk models may facilitate earlier identification of high-risk individuals and promote more aggressive preventive strategies^[55,169].

Despite these advances, significant challenges remain, including variability in access to molecular testing, lack of standardized protocols, and uncertainty in the interpretation of complex data. Addressing these limitations will be essential to fully translate postmortem insights into effective preventive strategies^[170,171]. Overall, the integration of forensic findings into cardiovascular risk stratification represents a paradigm shift toward a preventive, multidisciplinary approach in which insights derived from postmortem investigation directly inform clinical decision-making and public health policy.

Despite significant advances in forensic and molecular diagnostics, the investigation of SCD remains characterized by important practical challenges and unresolved controversies. These limitations are particularly evident in the application of advanced molecular and multi-omic techniques, where diagnostic potential often exceeds current feasibility in routine forensic practice.

A major area of uncertainty concerns autopsy-negative SCD, where the absence of structural findings complicates causal attribution. In these cases, molecular autopsy provides important insights; however, the high prevalence of VUS introduces interpretative ambiguity and may limit clinical translation. Similarly, toxicological findings often present causal dilemmas, particularly in the presence of polypharmacy or substances with known pro-arrhythmic potential, where distinguishing contribution from coincidence remains challenging^[50,91].

The strength of evidence supporting different diagnostic approaches is highly heterogeneous. Conventional autopsy and histology remain the gold standard for structural disease, supported by robust guideline-based evidence. In contrast, molecular autopsy offers moderate diagnostic yield, particularly in younger individuals, but is limited by interpretative complexity. Emerging approaches such as proteomics, metabolomics, and artificial intelligence demonstrate promising diagnostic potential but currently lack sufficient validation and standardization for routine forensic application^[95-97,172].

Accessibility and cost represent major barriers to implementation. Advanced diagnostic tools, including NGS, postmortem imaging, and multi-omics platforms, require significant infrastructure and expertise, resulting in unequal availability across forensic systems. These disparities contribute to variability in diagnostic accuracy and limit the widespread adoption of standardized protocols.

Ethical considerations are particularly relevant in the context of postmortem genetic testing. Issues related to consent, genetic privacy, and communication of results to relatives are compounded by the potential identification of uncertain or incidental findings. The need for structured genetic counseling and clear governance frameworks is increasingly recognized as an essential component of modern SCD investigation^[173].

Finally, substantial variability exists across judicial systems in terms of autopsy rates, investigative protocols, and reporting standards. These differences influence not only cause-of-death determination but also the integration of forensic findings into epidemiological surveillance and public health strategies. Harmonization of practices at an international level remains a critical priority to ensure comparability of data and equitable access to preventive interventions^[174].

An additional critical aspect concerns the marked heterogeneity of forensic practice across different legal and healthcare systems. In European countries with centralized medico-legal frameworks, such as Italy and Germany, autopsy rates in suspected SCD are relatively high and often guided by standardized protocols, with increasing integration of cardiovascular pathology and molecular testing in selected centers. In contrast, systems such as those of the United States, which rely on a mixed coroner and medical examiner structure, exhibit greater variability in autopsy practices, resource allocation, and access to specialized investigations, including postmortem genetic testing. In other regions, particularly in low- and middle-income countries, limited infrastructure and financial constraints may significantly restrict the use of advanced techniques, resulting in underdiagnosis or misclassification of SCD^[40,105].

These differences have important implications for data comparability, diagnostic accuracy, and the translation of forensic findings into cardiovascular risk assessment strategies. They also underscore the need for internationally harmonized guidelines, scalable diagnostic protocols, and collaborative networks aimed at reducing disparities and improving the overall quality of SCD investigation worldwide.

AI and computational pathology have attracted growing interest as potential tools for improving SCD investigation; however, their future role in routine forensic practice remains to be established. Recent studies demonstrate that machine-learning algorithms applied to digitized myocardial histology can identify features, such as micro-fibrosis patterns, adipocyte distribution, and regional myocardial composition, that are not readily apparent using conventional microscopy^[166,175].

These preliminary findings suggest that AI may eventually contribute to the re-evaluation of cases previously categorized as structurally normal, providing new insights into arrhythmogenic vulnerability. A practical example of this approach is the use of AI-assisted digital pathology to quantify myocardial fibrosis on whole-slide histological images. Automated algorithms can objectively assess the extent and distribution of interstitial and replacement fibrosis, reducing observer variability and improving reproducibility. In both clinical and forensic settings, such quantitative analyses may help distinguish physiological cardiac remodeling (“athlete’s heart”) from pathological HCM, where myocardial fibrosis represents a recognized substrate for ventricular arrhythmias and SCD^[65,87]. More broadly, AI-driven assessment of fibrosis patterns could potentially contribute to refining postmortem cardiovascular risk stratification and identifying subtle arrhythmogenic substrates that could be overlooked by conventional microscopy. Moreover, quantitative image analysis reduces interobserver variability, a well-recognized limitation in forensic pathology, and supports the development of reproducible diagnostic criteria across institutions^[145].

However, the implementation of AI in routine forensic practice remains limited by several factors, including the need for large, well-annotated datasets, standardization of analytical pipelines, and validation across diverse populations. In addition, the “black box” nature of many machine-learning models raises interpretative and medico-legal concerns. It should be emphasized that AI and computational pathology have not yet entered routine forensic practice in the investigation of SCD. Most published evidence originates from pilot studies, retrospective analyses, or proof-of-concept machine-learning models developed on relatively small datasets.

Despite these challenges, AI represents a promising area of investigation, although its role as a diagnostic support tool or predictive platform requires prospective validation before routine implementation can be recommended.

Standardization of autopsy protocols represents a critical step toward improving diagnostic accuracy, comparability of data, and translational impact of SCD investigations. Current practice remains heterogeneous across institutions, particularly in terms of tissue sampling, application of molecular testing, and reporting standards, which can lead to inconsistent diagnoses and missed opportunities for prevention^[51,176].

International initiatives, such as the Swiss multidisciplinary recommendations, provide a framework for harmonization, emphasizing systematic autopsy in unexplained cases, standardized myocardial sampling, preservation of biological material for genetic testing, and structured communication with families^[27,177]. Nevertheless, implementation of standardized protocols is challenged by disparities in resources, legal frameworks, and autopsy rates across countries. In addition, integration of molecular autopsy into routine workflows requires infrastructure, expertise, and ethical guidelines for managing genetic information^[50].

Future efforts should therefore focus on developing scalable, resource-adapted protocols and fostering international collaboration, as highlighted by global initiatives such as the Lancet Commission on SCD^[178]. These efforts should explicitly account for differences between legal systems, including coroner-based and medical examiner models, to ensure that proposed standards are adaptable across diverse jurisdictions.

Future developments must also address non-technical barriers, including cost-effectiveness, ethical governance, and legal harmonization. The integration of advanced diagnostics into routine practice will require scalable models adapted to different resource settings, as well as internationally shared guidelines to reduce variability across judicial systems. A pragmatic approach to implementation may include tiered diagnostic strategies, in which advanced techniques such as molecular autopsy are prioritized for selected cases, particularly young individuals and autopsy-negative deaths. The establishment of centralized reference laboratories, shared databases for variant interpretation, and international collaborative networks may further improve cost-effectiveness and diagnostic consistency across jurisdictions.

The integration of multidimensional datasets, including digital pathology, genomics, proteomics, and imaging, represents a promising future direction for both SCD research and forensic practice. Combining these data sources may enable comprehensive phenotyping of arrhythmogenic diseases and facilitate a transition from single-modality assessment to integrated diagnostic models.

Recent studies demonstrate that combining digital histology with genomic data can reveal subtle correlations between genetic variants and microstructural myocardial alterations, enabling more precise characterization of disease phenotypes^[95,166].

Similarly, integration of imaging with pathological and molecular data supports cross-validation of findings and improves classification of SCD subtypes^[96,146].

At the population level, large-scale data integration may facilitate the development of predictive models for SCD risk, aligning with global efforts to reduce sudden cardiac mortality through data-driven prevention strategies^[178,179].

However, significant challenges remain, including data standardization, interoperability between systems, ethical governance, and protection of sensitive genetic information. Most currently available models remain research-based, and evidence demonstrating improvements in forensic diagnostic accuracy or clinical prevention outcomes is still limited. Prospective multicenter studies would be needed to assess the actual translational value for these approaches.

Emerging biomarkers and molecular diagnostic tools may expand the ability to detect early myocardial injury and identify arrhythmogenic substrates, particularly in cases where conventional autopsy findings are inconclusive. Advances in proteomics, metabolomics, and RNA-based diagnostics provide insight into dynamic biological processes associated with ischemia, inflammation, and electrical instability^[50].

While traditional biomarkers remain useful, their postmortem interpretation is limited by issues such as redistribution and degradation. In contrast, multi-omic approaches have the potential to capture complex molecular signatures that reflect underlying pathophysiological mechanisms^[180].

Molecular autopsy continues to evolve beyond coding regions, with increasing attention to regulatory elements and non-coding variants that may contribute to inherited arrhythmogenic risk^[160].

Despite these advances, widespread clinical implementation is hindered by lack of standardization, limited validation, and challenges in data interpretation. Future research should focus on establishing reliable biomarker panels, defining diagnostic thresholds, and integrating molecular findings into multidisciplinary frameworks.